Alzheimer’s Research UK has hailed the drug lecanemab as a ‘truly historic moment’ for dementia research after trials found it can slow the rate of decline in people’s memory.
Results from a three-phase clinical trial have been published today by pharmaceutical company Eisai.
The data has shown that the drug can help Alzheimer’s patients over 18 months and help them with day-to-day activities.
The trial included 1,795 people in the early stages of the disease, who received bi-weekly infusions of either lecanemab or a placebo.
Alzheimer’s Research UK has said that the findings represent a ‘major step forward’ for dementia research.
They noted, however, that lecanemab did come with significant side effects.
Dr Susan Kohlhaas, Director of Research at Alzheimer’s Research UK, said: “These exciting findings represent a major step forward for dementia research and could herald a new era for people with Alzheimer’s disease. This is the first time a drug has been shown to both reduce the disease in the brain and slow memory decline in clinical trials.
“Lecanemab works by clearing the amyloid protein that builds up in the brain in people with Alzheimer’s disease. In this trial, the drug slowed down participants’ decline in memory and thinking, and their ability to carry out day-to-day activities. Although the benefits were small and came with significant side effects, it marks the arrival of a treatment that can slow the course of Alzheimer’s disease.
“With all this excitement, there are still many questions and challenges we need to address.
“The treatment window in the trial was for 18 months, so we don’t yet know whether there will be impacts to people that last beyond this. Longer-term studies that are ongoing will tell us whether the modest improvements seen in the trial change the trajectory of the disease longer-term.
“Lecanemab was associated with severe side effects, and it will be important for regulators to understand the safety profile of the drug before it is given a full license for use.
“The benefits of taking lecanemab in the trial were modest but the challenge and opportunity remains within dementia research to build on these findings into an era where we’re developing multiple treatments against different aspects of Alzheimer’s disease to slow and stop the disease.
“It’s safe to say that the NHS is not ready for a new era of dementia treatment.
“We estimate that unless there are drastic changes in how people access specialist diagnostic tests for Alzheimer’s disease, only 2% of people eligible for drugs like lecanemab will be able to access them. We recommend, through the new Dementia Mission, the government take urgent steps to bring together regulators, industry, clinicians and decision-makers in our health system to put a clear plan in place to ensure people in the UK are among the first in the world to access new treatments once they are licensed.
“This is truly a historic moment for dementia research. This year is the 30th anniversary of the seminal work that revealed the central role of amyloid protein in Alzheimer’s. The road to an anti-amyloid treatment has been a long one and people with Alzheimer’s have seen many disappointing setbacks.
“We hope that this drug will make it to patients, but it won’t be suitable for everyone with Alzheimer’s, and it’s only a first step on the journey towards a cure.”
Featured image: Unsplash
‘Sad news’ – the world’s only Vagina Museum has been forced to close
There’s a museum for just about everything these days (we all remember trips to the Stockport Hat Works museum) – but the world’s only space dedicated to vaginas has been forced to close again.
The world-first Vagina Museum announced this week that it’s had to vacate its premises and has once again been left ‘homeless’.
The museum, which welcomed 40,000 visitors in the 10 months it was open, was founded to raise awareness of the gynaecological anatomy and health, erase stigma, and act as a forum for feminism.
Inside, visitors could browse everything from educational materials to art pieces inspired by vaginas and vulvas – including giant tampons decorated in red sequins.
The Vagina Museum said it was ‘disappointed’ that it has been asked to leave its space, adding that it will continue to operate digitally until it finds a new base.
They wrote in a heartfelt statement on social media that they were ‘incredibly proud’ of the museum’s achievements.
Fans of the space queued down the street for its final few days in Bethnal Green, before its eventual closure on Wednesday 1 February.
Their statement said: “Sad news. We’ve received notice to vacate our premises at Bethnal Green by the end of this week. As a property guardianship, we’ve always been aware that we may be asked to leave with very short notice. We’re disappointed that it has come so soon.
“@Enter_theVenue the creative hub with whom we share our space, have also been asked to leave. The Vagina Museum will continue to operate in the digital world as we search for a new home.”
The message continued: “We’re sad about this development, but incredibly proud of what we’ve accomplished in the ten months we’ve been at our Bethnal Green premises. We’ve welcomed more than 40,000 visitors through our doors, and received so much love and positive feedback.
“In our time at Bethnal Green, we’ve once again demonstrated just how much the world needs and wants a Vagina Museum.
“Times are, once again, uncertain for us, but we’ve been through this before and risen stronger than ever. With a community like you supporting us, we know we can get through this too.
“We’re actively searching for a new home, and if you know of any vacant spaces (or have one yourself!) please don’t hesitate to reach out. In our home in Bethnal Green, we and ENTER demonstrated that we can transform an empty, unused building into a thriving heart of a community.
“If you don’t have a building, you can still help! Please consider making a donation; a donation of any size makes a huge difference and will help us to weather this storm, just as we’ve weathered storms before.”
The Vagina Museum concluded its thread with: “We’ve made it through a pandemic and a period of temporary homelessness before. With you, together, we can make it through this too.”
Gary Neville addresses ‘clumsy like’ on Tweet about Mason Greenwood ￼
Gary Neville has said that his liking of a tweet about Mason Greenwood has been ‘misinterpreted’.
The former Manchester United legend and football pundit set off a Twitter storm last night after he ‘liked’ two tweets by Nazir Afzal, and briefly retweeted one.
The tweets in question said that Greenwood was an ‘innocent man’ and added that ‘you are innocent until PROVEN guilty’.
Mason Greenwood had all criminal charges against him dropped by the Crown Prosecution Service.
He had faced allegations of rape, controlling and coercive behaviour, and assault, all against the same woman.
The CPS said that Greenwood case had been stopped because of ‘the withdrawal of key witnesses and new material that came to light’, adding that there was no longer a ‘realistic prospect of conviction’.
Several people noticed that Neville had liked a tweet about Greenwood’s ‘innocence’ and quickly challenged him on it.
One person shared a screenshot and wrote: “You have a massive platform and you’re liking bulls**t like this just because the monster plays for a team you support. you’re disgusting @GNev2.”
He posted: “I liked a tweet relating to the Mason Greenwood news this afternoon from Nazir Afzal. ( the former director of public prosecutions ).
“This like is being misinterpreted. It was a clumsy like as I obviously condemn any violence against women.”
Greenwood issued a short statement yesterday, writing: “I am relieved that this matter is now over and I would like to thank my family, loved ones and friends for their support. There will be no further comment at this time.”
Featured image: Instagram, @garyneville2 / publicity picture